Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

Adding to the checkpoint blockade armamentarium

Nature Medicine volume 25, pages 203–205 (2019)Cite this article

Subjects

Antitumor immunity can be enhanced by blocking NKG2A, an inhibitory receptor expressed on natural killer and T cells.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Inhibition of NKG2A enhances cancer-immune interactions.

References

  1. van Montfoort, N. et al. Cell 175, 1744–1755 e1715 (2018).

    Article  Google Scholar 

  2. André, P. et al. Cell 175, 1731–1743 e1713 (2018).

    Article  Google Scholar 

  3. Bastidas-Legarda, L.Y. & Khakoo, S.I. Immunology http://doi.org/10.1111/imm.13039 (2018).

  4. Gooden, M. et al. Proc. Natl Acad. Sci. USA 108, 10656–10661 (2011).

    Article  CAS  Google Scholar 

  5. Bossard, C. et al. Int. J. Cancer 131, 855–863 (2012).

    Article  CAS  Google Scholar 

  6. Kim, N. & Kim, H. S. Front. Immunol. 9, 2041 (2018).

    Article  Google Scholar 

  7. Vermorken, J. B. et al. J. Clin. Oncol. 25, 2171–2177 (2007).

    Article  CAS  Google Scholar 

  8. Kreiter, S. et al. Nature 520, 692–696 (2015).

    Article  CAS  Google Scholar 

  9. Gubin, M. M. et al. Nature 515, 577–581 (2014).

    Article  CAS  Google Scholar 

  10. Massarelli, E. et al. JAMA Oncol. 5, 67–73 (2019).

    Article  Google Scholar 

  11. Gunturi, A., Berg, R. E., Crossley, E., Murray, S. & Forman, J. Eur. J. Immunol. 35, 766–775 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Matthew D. Hellmann

  2. Weill Cornell Medical College, New York, NY, USA

    Matthew D. Hellmann

  3. Merck, Rahway, NJ, USA

    Alexandra Snyder

Authors
  1. Matthew D. Hellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Snyder.

Ethics declarations

Competing interests

A.S. is an employee of and owns stock in Merck. M.D.H. receives research funding from Bristol-Myers Squibb; is a paid consultant to Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs; receives travel support and honoraria from AztraZeneca and BMS; and has filed a patent related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hellmann, M.D., Snyder, A. Adding to the checkpoint blockade armamentarium. Nat Med 25, 203–205 (2019). https://doi.org/10.1038/s41591-019-0350-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0350-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing